Date: November 16-17, 2016
Venue: Durham Convention Center & Durham Marriott City Center, Durham, NC, USA
Through presentation and hands-on exercises, participants build a budget impact model and interpret the results. Starting with an overview of what a budget impact analysis is and why it is important, good practice guidelines and the six basic steps that must be completed to determine the current budget will be explored. These steps are: 1) estimating the target population; 2) selecting a time horizon; 3) identifying current and projected treatment mix; 4) estimating current and future drug costs; 5) estimating change in disease-related costs; and 6) estimating and presenting changes in annual budget impact and health outcomes. To illustrate these steps, we will guide participants through the construction of a budget impact model using data sources provided. Participants will work with the Faculty to create each component of the budget impact analysis, thus gaining an understanding of its structure and the calculations. They will also interpret results, consider critical questions to consider when adapting a budget impact analysis to their own health plan, and review how these analyses are used by payers and other decision makers. The course will cover technical topics such as use of static versus dynamic budget impact models and differences between budget impact analyses for drugs compared with those for device or diagnostic technologies.
Josephine A. Mauskopf, PhD, MHA, MA
Josephine Mauskopf, PhD, MHA, MA, is Vice President of Health Economics at RTI HS. She has extensive experience both as a consultant and within the pharmaceutical industry designing and implementing pharmacoeconomic research strategies. She has designed pharmaco¬economic research programs for drugs for bacterial infections, viral infections, psychiatric illness, and neurologic diseases. Dr. Mauskopf has estimated budget impacts for new products for schizophrenia, bipolar disease, breast cancer, and HIV infection. She has estimated the cost-effectiveness of antiretroviral drugs, as well as drugs for treating Alzheimers disease, fungal infections, herpes zoster, epilepsy, neonatal respiratory distress syndrome, digoxin toxicity, community-acquired pneumonia, intra-abdominal infections, influenza vaccination, and primary pulmonary hypertension. Dr. Mauskopf also has estimated the impact of an antidepressant on work and social disability. Dr Mauskopf has performed many strategic literature reviews that have been published in peer-reviewed journals, including reviews of cost of care for Alzheimer disease, cost of care for treatment-resistant depression, a review of the methods used to estimate the cost-effectiveness of vaccine programs using dynamic programming models, cost-effectiveness of tiotropium for chronic obstructive pulmonary disease, and treatments for uterine fibroids. Dr. Mauskopf has developed Markov models of disease progression for lung cancer and HIV infection and has developed simulation models of time spent in the operating and recovery rooms and of disease progression for HIV infection.
Dr. Mauskopf was previously Vice President at MEDTAP International, Department Head of Economics Research at Burroughs Wellcome Co., and Director of Pharmacoeconomics Research for Anti-Virals and Anti-Infectives at Glaxo Wellcome Inc. Dr. Mauskopf has completed an 8-year term as Editor-in-Chief of the journal Value in Health. She served for 4 years as a reviewer on the Health Care Technology and Decision Sciences Study Section at the Agency for Healthcare Research and Quality (ARHQ). She is currently serving on the ISPOR Board as a Director. She has presented her research at numerous national and international symposia. She has also published extensively in journals, including Journal of the American Medical Association, Journal of Pediatrics, Journal of Medical Economics, Health Policy, PharmacoEconomics, Value in Health, Medical Care, American Journal of Public Health, Health Services Research, American Journal of Alzheimers Disease and Other Dementias, and Journal of Nutrition, Health, and Aging.
Stephanie R. Earnshaw, PhD, MS
Stephanie Earnshaw is Vice President of Health Economics at RTI Health Solutions (RTI HS). She received her PhD in Industrial Engineering at North Carolina State University and has been with RTI-HS for over 17 years. She has presented workshops, distance learning, and short courses on decision-analytic modeling techniques for pharmaceutical companies and organizations such as the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the Academy of Managed Care Pharmacy (AMCP), and the Centers for Disease Control and Prevention (CDC). Dr. Earnshaw has also held an adjunct faculty appointment at the University of North Carolina’s Eshelman School of Pharmacy, Division of Pharmaceutical Outcomes and Policy.
Dr. Earnshaw applies mathematical modeling, optimization, and decision-analysis techniques to industry-related issues and health care problems. Her areas of specialization include systems optimization and solving resource allocation problems. She has developed innovative mathematical models to determine pricing strategy and to assess impact to budgets and cost-effectiveness of health technologies in cardiovascular disease, gastrointestinal disorders, chronic obstructive pulmonary disease, transplantation, infectious disease, osteoporosis, and mens health. Mathematical modeling techniques performed include mathematical programming (linear and integer), network optimization, Markov, Monte Carlo simulation, and other state transition models. These analyses have been used to support not only pharmaceuticals, but also diagnostics and medical devices. She is a member of the International Society for Pharmacoeconomics Outcomes Research and the Institute for Operations Research and the Management Sciences. She has presented her work at professional conferences and has published in several peer-reviewed journals.
C. Daniel Mullins, PhD
C. Daniel Mullins, PhD is a Professor and Chair of the Pharmaceutical Health Services Research Department at the University of Maryland School of Pharmacy. He received his BS in Economics from M.I.T. and his PhD in Economics from Duke University. His research and teaching focus on comparative effectiveness research (CER), patient-centered outcomes research (PCOR), pharmacoeconomics, and health disparities research. He directs the University of Maryland PATient-centered Involvement in Evaluating effectiveNess of TreatmentS (PATIENTS) Program, which received a University of Maryland Baltimore Champion of Excellence Award. He has received funding as a Principal Investigator from the NIH/NIA, NIH/NHLBI, AHRQ, and the Patient-Centered Outcomes Research Institute (PCORI) and was the Shared Resources Core Director for the NIH-sponsored University of Maryland Center for Health Disparities Research, Training, and Outreach. He previously served as a Regular Member of the AHRQ HSR and the NCI-J Study Sections and currently serves as a Regular Member for the AHRQ HCRT Study Section. He also has chaired PCORI Study Sections.
In addition to his work on federal grants, Professor Mullins is co-Editor-in-Chief for Value in Health and is author/co-author of approximately 200 peer-reviewed articles and book chapters on pharmacoeconomics, outcomes research, and pharmaceutical policy and health disparities research in journals such as The American Journal of Managed Care, The American Journal of Public Health, Cancer, Chest, Health Affairs, Health Services Research, JAMA, Journal of Clinical Oncology, Pharmacoeconomics, and Social Science & Medicine. He has received an Outstanding Service Award from the Drug Information Association (DIA) and two Service Awards from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). In 2007, he received the Dr. Patricia Sokolove Outstanding Mentor Award from the University of Maryland, Baltimore campus-wide Graduate Student Association. In 2013, he was the recipient of the Dr. Daniel D. Savage Memorial Science Award, the Association of Black Cardiologists’ most prestigious annual award. Also in 2013, he was awarded a University System of Maryland Wilson H. Elkins Professorship. In 2014, he and Robin Newhouse were named co-researchers of the year for the University of Maryland Baltimore campus.
Anita Brogan, PhD, MS
Anita Brogan is Head of Decision Analytic Modeling within the Health Economics division at RTI Health Solutions (RTI-HS). She holds a PhD in Operations Research from the University of North Carolina and has been with RTI-HS for 13 years. She has presented workshops and short courses on decision-analytic modeling techniques in a variety of venues, including meetings of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the Academy of Managed Care Pharmacy (AMCP). Dr. Brogan has also held an adjunct professorship in the Fermanian School of Business at Point Loma Nazarene University.
In her role at RTI-HS, Dr. Brogan uses analytical techniques to assess and present the clinical and economic value of emerging pharmaceutical and biotechnology products. She leads development of user-friendly and transparent cost-effectiveness, cost-utility, and cost-consequence models; budget-impact models; resource allocation models; and infectious disease transmission models programmed in Microsoft Excel and other platforms. She has experience with numerous types of modeling procedures, including Markov and other stochastic models, simulation, regression, linear and nonlinear programming, and various types of sensitivity analysis. Dr. Brogan has developed models and analyses in the areas of HIV, hepatitis C, influenza, mental health, women’s health, diabetic nephropathy, oncology, osteoporosis, chronic pain, age-related macular degeneration, bone healing, hospital-acquired infection, financial portfolio optimization, and vehicle routing. Her research has been presented at various professional conferences and published in peer-reviewed journals.